Ligand Pharmaceuticals Incorporated (LGND)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-4,032	45,244	39,624	93,825	49,635	16,913	30,109	26,924	-30,410	-20,844	-7,525	24,095	57,586	68,315	47,891	39,252	-2,985	-16,111	-24,661	-61,166
Total assets	US$ in thousands	941,774	954,866	866,405	913,869	833,064	769,210	758,105	811,076	762,668	1,051	1,076,290	1,105,180	1,301,380	1,273,660	1,256,280	1,295,120	1,362,280	1,247,450	1,242,940	1,185,920
ROA		-0.43%	4.74%	4.57%	10.27%	5.96%	2.20%	3.97%	3.32%	-3.99%	-1,983.25%	-0.70%	2.18%	4.42%	5.36%	3.81%	3.03%	-0.22%	-1.29%	-1.98%	-5.16%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $-4,032K ÷ $941,774K
= -0.43%

Ligand Pharmaceuticals Incorporated's return on assets (ROA) has shown fluctuations over the provided period. The ROA was negative for most of 2020 and the first half of 2021, indicating the company was not effectively utilizing its assets to generate profit during that time. However, the ROA turned positive in March 2021 and showed consistent improvement, reaching a peak of 10.27% in March 2024.

The positive ROA values from March 2021 onwards suggest that Ligand Pharmaceuticals Incorporated has been able to generate more profits relative to its assets during this period. The company's ability to improve its ROA indicates a more efficient use of assets to create value for shareholders.

It is worth noting that there were significant negative ROA values in September 2022 and December 2022, which could indicate challenges or setbacks faced by the company during these periods in terms of generating profits from its assets. Overall, the trend of increasing ROA values in recent periods reflects positively on Ligand Pharmaceuticals Incorporated's performance in terms of asset utilization and profitability.